Remove

U.S. Patent and Trademark Offi Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unite

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

	Application Number		10708242					
	Filing Date		2004-02-18					
	First Named Inventor	Ling-\	Yı Liu					
	Art Unit		2111					
	Examiner Name RAY,		GOPAL C					
Attorney Docket Number			IFTP0002USA9					

					U.S.	PATENTS	Remove					
Examiner Initial* Cite No Patent Number Kind Code1				Issue Date Name of Patentee or Applicant of cited Document			Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear					
	1	5987566		1999-11	1-16	Vishlitzky						
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.	_	Add			
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove			
Examiner Initial*	aminer Cite No Publication Number Kind Code Date Name of Patentee or Applic			Releva		Lines where						
	1	20040177218	A1	2004-09	9-09	Meehan						
	2	20020152355	A1	2002-10	D-17	Otterness						
	3	20050182887	A1	2005-08	3-18	Sakurai						
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	please click the Ad	d buttor		]		
				FOREIG	GN PAT	ENT DOCUM	IENTS		Remove			
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date Name of Pate Applicant of coursent		e or	where Re	or Relevant	Ts	
	1										Г	

II S DATEMES

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Numb Filing Date First Named Invert Art Unit Examiner Name

Application Number		10708242				
Filing Date		2004-02-18				
First Named Inventor	Ling-\	fı Liu				
Art Unit		2111				
Examiner Name	RAY,	GOPAL C				
Attorney Docket Numb	er	IFTP0002USA9				

If you wisl	h to a	dd add	ditional l	oreign f	atent	Docur	ment c	citation	n infor	mation p	lease o	lick the Ad	d buttor	ı A	dd			
					N	ON-P	ATEN	IT LITE	ERAT	URE DO	CUME	NTS		Ren	nove			
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the intoles* No No window, magazine, journal, sorial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher.								item	Ţ5									
	1																	-
If you wisl	h to a	dd add	ditional r	on-pate	nt litera	ature (	docum	ment cit	itation	informat	tion ple	ase click th	e Add I	outton	Ad	d		
							EXA	AMINE	R SIG	GNATUR	RΕ							
Examiner	Signa	ture									0	ate Consid	ered					
	EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																	

1 See Kind Code of USFTO Planto Documents at year, <u>USFTO CODY</u> or MEPD 910.4. <sup>2</sup> Enter office that issued the cocument, by the two-letter code (WPD Standard ST3.). <sup>2</sup> The Japanese parted coverents, the relication to the year of the region of the Emperor must proceed the serial number of the papert document of the Standard ST3.0 <sup>2</sup> Serial ST3.0 <sup>2</sup> Serial Standard ST3.0 <sup>2</sup> Serial ST3.0 <sup>2</sup> Serial Standard ST3.0 <sup>2</sup> Serial ST3.0 <sup>2</sup> S

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10708242				
Filing Date		2004-02-18				
First Named Inventor Ling-Y		fı Liu				
Art Unit		2111				
Examiner Name RAY,		GOPAL C				
Attorney Docket Numb	ec	IFTP0002USA9				

#### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the	appropriate	selection(s):	
---------------	----------	-------------	----------	-------------	---------------	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a deeping patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to item individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.57(c) The 1.57(c) the control of the control

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- \_ ....

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/WINSTON HSU/	Date (YYYY-MM-DD)	2007-08-14
Name/Print	WINSTON HSIJ	Registration Number	41526

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandriva, V.S. 2311-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.